Delta 9 Cannabis Inc. T.DN

Alternate Symbol(s): DLTNF

Healthcare Cannabis

Delta 9 Cannabis Inc. is a Canada-based vertically integrated cannabis company. The Company operates through three segments: Wholesale Cannabis, Retail Cannabis and Merchandise and Devices, and Business to Business. The Company sells cannabis products through its wholesale and retail sales channels and sells its cannabis growing pods to other businesses. Its cannabis products include dried cannabis and pre-rolled joints. Its edibles and vapes include vape pens and concentrates, edibles, and drinkables. The Company, through its wholly owned subsidiary, Delta 9 Bio-Tech Inc., is a licensed producer of medical and recreational cannabis products and operates a 95,000-square-foot Health Canada licensed production facility in Winnipeg, Manitoba, Canada. It also owns and operates a chain of retail stores under the Delta 9 Cannabis Store brand. It is focused on producing and selling cannabis oils, extracts, and derivative products.

TSX:DN - Post by User

Delta 9 Cannabis Inc.

<< Previous

Bullboard Posts

Next >>

Post by Canadaforoilon Dec 17, 2020 10:20pm

148 Views

Post# 32137496

IFRS standards

So I get the reporting standards and thought that is why they separate out the unrealized/realized gain on bio assets. See below:

Cost of Sales	7,356,889	6,858,370	8,394,239	9,168,026
Gross Profit Before Unrealized Gain From Changes In Biological Assets	3,228,595	4,895,036	4,619,371	3,962,294
Unrealized gain from changes in fair value of biological assets (Net)	1,991,398	2,761,873	2,460,490	(2,338,699)

So I thought these two lines would deal with the bio assets and fair reporting without affecting cost of sales. Maybe I am missing something here, debentures, can you explain it differently?

<< Previous

Bullboard Posts

Next >>

Bombardier partially redeems US$788 million in senior notes